$31.17
+2.17 (+7.48%)
Open$28.70
Previous Close$29.00
Day High$32.00
Day Low$26.45
52W High$910.00
52W Low$15.10
Volume—
Avg Volume22.7K
Market Cap31.02M
P/E Ratio—
EPS$-125.71
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+28.8% upside
Current
$31.17
$31.17
Target
$40.14
$40.14
$31.69
$40.14 avg
$63.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 548.9K | 523.5K | 509.5K |
| Net Income | 128.1K | 108.5K | 123.6K |
| Profit Margin | 23.3% | 20.7% | 24.3% |
| EBITDA | 177.1K | 173.7K | 174.5K |
| Free Cash Flow | 145.7K | 139.2K | 108.0K |
| Rev Growth | +23.9% | +19.4% | -4.0% |
| Debt/Equity | 0.65 | 0.64 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |